Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence crossover study of darunavir/cobicistat/emtricitabine/tenofovir alafenamide fixed-dose combination versus separate agents
NL-OMON42760Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of darunavir, cobicistat, emtricitabine and tenofovir alafenamide in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Single-dose pharmacokinetics and pivotal bioequivalence of darunavir, emtricitabine, and tenofovir alafenamide. Started Dec 2015; status: active, not recruiting.
02
Drugs
darunavircobicistatemtricitabinetenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON42760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42760.